Loading
A phase 2 trial of Nivolumab, Ipilimumab, Cabozantinib, Trametinib, Capecitabine and Bevacizumab in advanced solid tumours, run by Bristol-Myers Squibb, now recruiting.
Pan Tumor Rollover Study is a phase 2 interventional study registered as NCT03899155 by Bristol-Myers Squibb, with 1500 participants planned, started 2019-08-09 and due to reach its primary completion in 2029-08-25. Interventions recorded: Nivolumab, Ipilimumab, Cabozantinib, Trametinib, Relatlimab and Nivolumab + Relatlimab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Ipilimumab, Bristol Myers Squibb, Nivolumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Bristol Myers Squibb, Bevacizumab, Nivolumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Bristol Myers Squibb, Nivolumab, Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Novartis, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Novartis, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Ipilimumab, Bevacizumab, Nivolumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Novartis, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/